000			01892 a2200565 4500
005			20250517162416.0
264		0	_c20180613
008			201806s 0 0 eng d
022			_a1872-7913
024	7		_a10.1016/j.ijantimicag.2017.05.017 _2doi
040			_aNLM _beng _cNLM
100	1		_aPaiva, J A
245	0	0	_aDrivers and impact of antifungal therapy in critically ill patients with Aspergillus-positive respiratory tract cultures. _h[electronic resource]
260			_bInternational journal of antimicrobial agents _cOct 2017
300			_a529-535 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAged
650	0	4	_aAmphotericin B _xtherapeutic use
650	0	4	_aAntifungal Agents _xtherapeutic use
650	0	4	_aAspergillus _xdrug effects
650	0	4	_aClinical Decision-Making
650	0	4	_aCritical Illness
650	0	4	_aDelayed Diagnosis _xmortality
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEchinocandins _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aFungal Proteins _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aIntensive Care Units
650	0	4	_aInvasive Pulmonary Aspergillosis _xdiagnosis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPrognosis
650	0	4	_aRespiratory System _xmicrobiology
650	0	4	_aTreatment Outcome
650	0	4	_aVoriconazole _xtherapeutic use
700	1		_aMergulhão, P
700	1		_aGomes, A
700	1		_aTaccone, F S
700	1		_aVan den Abeele, A-M
700	1		_aBulpa, P
700	1		_aMisset, B
700	1		_aMeersseman, W
700	1		_aDimopoulos, G
700	1		_aRello, J
700	1		_aVogelaers, D
700	1		_aBlot, S
773	0		_tInternational journal of antimicrobial agents _gvol. 50 _gno. 4 _gp. 529-535
856	4	0	_uhttps://doi.org/10.1016/j.ijantimicag.2017.05.017 _zAvailable from publisher's website
999			_c27331203 _d27331203